ArticleCancer medicine2026
Machine Learning-Based Profiling of Urinary Volatile Organic Compounds Reveals Distinct Diagnostic Signatures for Gastric Cancer.
Article in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionGastric cancer (GC) is a leading cause of cancer-related mortality worldwide, often diagnosed at advanced stages due to the absence of specific symptoms. This study aimed to explore the potential of urinary volatile organic compounds (VOCs) as non-invasive biomarkers for gastric cancer diagnosis.
methodsUrine samples from 60 GC patients and 65 healthy controls (HC) were analyzed via gas chromatography-ion mobility spectrometry (GC-IMS), detecting 84 VOCs. Machine learning algorithms-LASSO, SVM-RFE, and Boruta-were applied to select diagnostic biomarkers. Predictive models were constructed using the H2O AutoML framework, with the dataset randomly partitioned into training and test sets at an 7:3 ratio. The training set underwent 5-fold cross-validation to develop and optimize the models, and the resulting optimal model was validated on the reserved test set using metrics including the area under the curve (AUC), sensitivity, and specificity.
resultsA total of 84 VOC peaks were detected in the urine samples from GC patients. The OPLS-DA model successfully distinguished between the GC and control groups, indicating distinct metabolic features. The LASSO model demonstrated superior diagnostic performance, identifying a panel of six characteristic VOCs with high sensitivity and specificity. Moreover, a stacked ensemble model achieved an AUC of 0.93 (95% CI: 0.87-0.99) in the training set and 0.92 (95% CI: 0.83-1.00) in the test set, with 100% sensitivity (95% CI: 82.4%-100.0%) and 84% specificity (95% CI: 64.0%-94.8%), demonstrating substantial value for GC diagnosis.
conclusionsOur findings suggest that urinary VOCs may serve as promising non-invasive biomarkers for the diagnosis of gastric cancer. The identification of these VOCs provides valuable insights into the metabolic alterations associated with GC and highlights the potential for integrating VOC profiling into clinical practice for improved diagnostic strategies. Further validation in larger cohorts is warranted to confirm the clinical applicability of these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.